Institution
Eastern Cooperative Oncology Group
Facility•Philadelphia, Pennsylvania, United States•
About: Eastern Cooperative Oncology Group is a facility organization based out in Philadelphia, Pennsylvania, United States. It is known for research contribution in the topics: Cancer & Breast cancer. The organization has 249 authors who have published 170 publications receiving 26514 citations. The organization is also known as: ECOG.
Topics: Cancer, Breast cancer, Chemotherapy, Leukemia, Hazard ratio
Papers published on a yearly basis
Papers
More filters
••
TL;DR: EPO administration was associated with a significant increase in Hgb and a decrease in the transfusion requirement in anemic patients with MDS, and low doses of G-CSF + EPO were effective in EPO nonresponsive or refractory patients.
21 citations
••
TL;DR: Long‐term results from a phase 3 randomized trial that compared treatment with low‐dose 13‐CRA versus placebo for patients who had early stage SCCHN with a focus on the development of SPTs and overall survival (OS) are reported.
Abstract: BACKGROUND
13-Cis retinoic acid (13-CRA) is a synthetic vitamin A derivative. High-dose 13-CRA in patients with squamous cell cancers of the head and neck (SCCHNs) reduces the incidence of second primary tumors (SPTs). The authors report long-term results from a phase 3 randomized trial that compared treatment with low-dose 13-CRA versus placebo for patients who had early stage SCCHN, with a focus on the development of SPTs and overall survival (OS).
METHODS
In total, 176 patients who received treatment for stage I/II SCCHN were randomized to receive either low-dose 13-CRA (weight-based dose of 7.5 mg or 10 mg) or placebo for 2 years. A competing-risk approach and the log-rank test were used to compare the time to SPT and OS, respectively, between groups.
RESULTS
13-CRA neither significantly reduced the cumulative incidence of SPT (P = .61) nor improved the time to SPT (hazard ratio [HR] for 13-CRA/placebo; 0.86; P = .61). Despite limited power, there was a trend toward improved OS for the 13-CRA arm (HR, 0.75; P = .14), particularly among patients whose index tumor was surgically excised (N = 26; HR, 0.50; P = .057) and among women (N = 39; HR, 0.44; P = .065) and never/former smokers (N = 129; HR, 0.61; P = .055), with a median follow-up of 16 years. The main 13-CRA related toxicities were dry skin and cheilitis.
CONCLUSIONS
Treatment with low-dose 13-CRA for 2 years did not decrease the incidence of SPT; subset analysis indicates a potential survival advantage among patients who are women and never/former smokers. More targeted interventions based on clinical risk factors and molecular characterization of tumors may yield greater success in future prevention trials. Cancer 2017;123:4653-4662. © 2017 American Cancer Society.
20 citations
••
TL;DR: Therapy with DD is tolerable and modest efficacy was observed in SLL subtype and measured IL-2R status did not correlate with efficacy, according to this phase II trial.
Abstract: Denileukin diftitox (DD) is approved for treatment of CD-25 expressing cutaneous T-cell lymphomas (CTCL). Initial studies of DD demonstrated responses in patients with B-cell non-Hodgkin lymphoma (NHL). This phase II trial evaluated response rate (RR) and tolerability of DD in this population. Patients were stratified into two arms: those with NHL expressing > or =20% IL-2R (IL-2R+) or <20% IL-2R (IL-2R-). DD was dosed at 18 microg/kg/day for 5 days every 21 days. Corticosteroid pre-medication was not allowed. Thirty-five patients of a planned 77 accrued due to closure for slow accrual. This report is on 29 patients (18 males) with indolent B-cell NHL (11 IL-2R+ and 18 IL-2R-). Histologic subtypes included small lymphocytic (SLL) (8 patients) and follicular grade I/II lymphoma (21 patients). Patients received a median of three prior regimens, including rituximab in 76%. Three partial responses were observed (RR 10%). The RR for the IL-2R- and IL-2R+ patients was 11% and 9%, respectively. Of 8 patients with SLL, 2 responded. Toxicities were generally grade I - II and transient but 1 patient experienced a fatal thrombo-embolism. Therapy with DD is tolerable and modest efficacy was observed in SLL subtype. Measured IL-2R status did not correlate with efficacy.
20 citations
••
TL;DR: When conducting a clinical trial, it is important that clinical investigators successfully meet all research expectations, including regulatory requirements and the Guidelines for Good Clinical Practice.
Abstract: When conducting a clinical trial, it is important that clinical investigators successfully meet all research expectations, including regulatory requirements and the Guidelines for Good Clinical Practice.
20 citations
••
TL;DR: 5‐FU was effective only in ambulatory patients, whereas responses among non‐ambulatory patients were seen only in the group treated with Methyl‐CCNU, which was associated with the least drug‐related toxicity.
Abstract: In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks. On failure or progression, 133 protocol patients crossed-over to a secondary therapy, while 116 other patients previously treated with 5-fluorouracil off protocol were randomized to treatment with Methyl CCNU or B-2'-deoxythioguanosine. Response rates among patients who had received no prior chemotherapy were 18% to oral 5-FU, 15% to intravenous 5-FU and to MeCCNU, 12% to 5-FU and 6-thioguanine and 5% to cyclophosphamide and 5-FU, with little activity (3% response rate) in crossover or previously treated patients. Treatment with 5-FU, particularly oral 5-FU was associated with the least drug-related toxicity. Hematologic toxicity was greatest with Methyl CCNU, but was no more frequent in previously treated than in untreated patients. A tendency toward cumulative bone marrow depression was noted. 5-FU was effective only in ambulatory patients, whereas responses among non-ambulatory patients were seen only in the group treated with Methyl-CCNU.
19 citations
Authors
Showing all 249 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Cella | 156 | 1258 | 106402 |
Donna Neuberg | 135 | 810 | 72653 |
Stanley R. Hamilton | 126 | 441 | 94831 |
Martin S. Tallman | 117 | 917 | 60011 |
Al B. Benson | 113 | 578 | 48364 |
Richard Gray | 109 | 808 | 78580 |
David H. Johnson | 103 | 488 | 55925 |
Nancy E. Davidson | 99 | 384 | 63544 |
Michael A. Carducci | 91 | 574 | 39457 |
George P. Canellos | 88 | 343 | 32151 |
Hillard M. Lazarus | 88 | 575 | 31572 |
John M. Bennett | 88 | 458 | 54128 |
Antonio C. Wolff | 82 | 378 | 41408 |
Rebecca Gelman | 81 | 283 | 34736 |
Edward A. Stadtmauer | 81 | 427 | 28392 |